Fda authorizes quest diagnostics' proprietary monkeypox test for emergency use

First lab-developed test specifically designed to detect monkeypox virus dna to receive emergency use authorization during the monkeypox public health emergency secaucus, n.j. , sept. 7, 2022 /prnewswire/ -- quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, today announced that it has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the monkeypox virus.
DGX Ratings Summary
DGX Quant Ranking